CORBUS PHARMACEUTICALS

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum i... s currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus is also developing a pipeline of drug candidates from more than 600 novel compounds targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist. Potential indications for CRB-4001 include NASH, among others. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study.

#SimilarOrganizations #People #Financial #Event #Website #More

CORBUS PHARMACEUTICALS

Social Links:

Facebook

Twitter

Industry:

Biotechnology Clinical Trials Pharmaceutical

Founded:

2009-01-01

Address:

Norwood, Massachusetts, United States

Country:

United States

Website Url:

http://www.corbuspharma.com

Total Employee:

51+

Status:

Active

Contact:

(617) 963-0100

Email Addresses:

[email protected]

Total Funding:

196.95 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Domain Not Resolving